Evidence map›Paper›PMID 40112243›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen.

Anne-Sophie Brunel, Claire Seydoux, Sabine Schmidt, Siham Ahlyege, Aurélie Guillet, Katerina Mandralis, Mapi Fleury, Anne Cairoli, Sabine Blum, Olivier Spertini and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Characterization and outcomes of severe complications after autologous hematopoietic stem-cell transplantation: a retrospective multicenter study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anne-Sophie BrunelInfectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0001-9437-1977
Claire SeydouxService and Central Laboratory of Hematology, Department of Oncology and Department of Laboratories and Pathology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland.
Sabine SchmidtDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Siham AhlyegeService and Central Laboratory of Hematology, Department of Oncology and Department of Laboratories and Pathology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland.
Aurélie GuilletInfectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Katerina MandralisDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0001-7874-6337
Mapi FleuryDepartment of Oncology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland.ORCID 0000-0002-4462-9201
Anne CairoliService and Central Laboratory of Hematology, Department of Oncology and Department of Laboratories and Pathology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland.
Sabine BlumService and Central Laboratory of Hematology, Department of Oncology and Department of Laboratories and Pathology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland.
Olivier SpertiniService and Central Laboratory of Hematology, Department of Oncology and Department of Laboratories and Pathology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland.ORCID 0000-0002-1669-9421
Oscar MarchettiInfectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Mathilde GavilletService and Central Laboratory of Hematology, Department of Oncology and Department of Laboratories and Pathology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland.
Pierre-Yves BochudInfectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-2208-4757

Funding

Leenaards FoundationPromex Stiftung fur die Forschung (via Carigest SA)Santos-Suarez FoundationSwiss National Science Foundation 314730_192616Swiss National Science Foundation 31CA30_196036Swiss National Science Foundation 33IC30_179636
6 · The paper itself

Abstract

backgroundWhile neutropenic enterocolitis (NEC) is a well-known life-threatening complication during intensive chemotherapy, its incidence, impact, and outcome on specific at-risk populations remain ill defined.

methodsWe report 178 NEC episodes during 1963 myeloablative chemotherapy courses among 1259 adult patients with acute myeloid (AML) or lymphoblastic (ALL) leukemia or receiving autologous hematopoietic stem cell transplantation (auto-HCT) for lymphoma or multiple myeloma. Risk factors were assessed by multivariate logistic regression models.

resultsMost NEC cases (93.3%) occurred during AML induction (n = 92; 13.8% of chemotherapy course) and auto-HCT (n = 74; 9.5%). Independent risk factors for NEC during AML induction included high-dose corticosteroids (OR = 2.07; 95% CI: 1.29-3.30; P = .002), elevated circulating blasts at the time of diagnosis (>50 Giga/L; OR = 2.02; 95% CI: 1.15-3.56; P = .02), and use of azacitidine (OR = 2.45; 95% CI: 1.01-5.90; P = .05); purine-based regimens (eg, FLAG-Ida) were an independent protective factor (OR = .27; 95% CI: .15-.47; P < .001). Independent risk factors after auto-HCT included BEAM (carmustine, etoposide, cytarabine, and melphalan) versus another conditioning protocol (OR = 3.28; 95% CI: 1.98-5.43; P < .001) and age (OR = 1.03/year; 95% CI: 1.01-1.06; P = .007). For both AML induction and auto-HCT, NEC was associated with longer hospitalization (P = .03 and <.001), sepsis (quick SOFA ≥2; P = .03 and <.001), fungemia (P < .001 and P = .01), and intensive care admission (P = .03 and <.001, respectively). NEC was associated with increased in-hospital mortality during AML induction (6.5% vs 2.4%; P = .04) but not during auto-HCT (P = .3).

conclusionsThe incidence of NEC depended on chemotherapeutic regimens, with higher occurrence during standard "7 + 3" AML induction and BEAM conditioning for auto-HCT. NEC was associated with longer hospitalization and increased morbidity, but 30-day mortality was lower than previously reported.

Indexed as

acute leukemiaautologous hematopoietic stem cell transplantationchemotherapyhematological malignanciesneutropenic enterocolitis

Identifiers

PMID40112243
PMCPMC13017227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.